Fill out the form and we’ll get back to you directly
Full Name:
Phone number:
How we can help you?
Dr. Jair Bar is an expert in Thoracic Oncology
Dr. Jair Bar, M.D. Ph.D.
Head of Thoracic Oncology Unit, Institute of Oncology, Chaim Sheba Medical Center, Tel-Hashomer, Israel
Dr. Bar specializes in thoracic malignancies, including lung cancer (small cell or non-small cell), thymic carcinoma, thymoma, mesothelioma
Hebrew & English
Education & Fellowships
  • The Hebrew University-Hadassah Medical School, Jerusalem, Israel
  • Residency in Oncology (Medical and Radiotherapy), Oncology Institute, Chaim Sheba Medical Center, Tel-Hashomer, Israel
  • Fellowship in Medical Oncology, Thoracic Medical Oncology, The Ottawa Hospital, Ottawa, ON
  • Board certifications – Medical & Radiotherapy Oncology
Career Accomplishments
  • Head Medical & Radiation Oncology ,Thoracic Oncology, Chaim Sheba Medical Center, Tel-Hashomer, Israel
  • Chairman of the Israel Lung Cancer Group since March 2013
  • Principle Investigator on all lung cancer trials in the Sheba Oncology Institute since 2011
  • Head of a research lab at the Sheba Cancer Research Center
  • Member of Israel Medical Association (IMA)
  • Member of Israel Society for Clinical Oncology and Radiotherapy (ISCORT)
  • Member of American Association for Cancer Research (AACR)
  • Member of American Society of Clinical Oncology (ASCO)
  • Teaching medical school students and residents at the Sheba Medical Center, Israel, and at The Ottawa Hospital, Ottawa, Canada
  • Dr Bar is the author of many research articles, review articles, book chapters on the issue of lung cancer and its treatment
Research Interests
Dr. Bar is involved in clinical, basic and translational research in the field of lung cancer treatments, aiming to identify novel therapies and to elucidate ways to predict which patients will benefit from which treatment. Specific ongoing research projects:
  • Clinical studies:
    • A study of a novel drug, afatinib, in the treatment of lung cancer patients with an EGFR mutation, after failure of first line treatment with erlotinib (Tarceva) or gefitinib (Iressa)
    • A study of the interests of lung cancer patients in terms of information they want to know about their cancer
  • Translational research:
    • Identification of a gene expression signature of lung cancer tumors that can identify a high risk for metastatic spread of disease to specific organs - aiming to allow in the future organ-directed preventive treatments (such as preventive treatments to bone or to brain)
    • Analysis of features of lung cancer of adenocarcinoma type that can predict better efficacy of treatment
  • Basic research:
    • A study of the interaction of cancer cells with other types of cells present in a tumor mass and the contribution of these interactions to tumor growth. This will allow identification of novel therapeutic targets in lung cancer.
    • A study of the role of a gene called FoxM1 in the growth of lung cancer